×

Use of inhibitors for the treatment of disorders related to RTK hyperfunction, especially cancer

  • US 6,770,742 B1
  • Filed: 09/07/2000
  • Issued: 08/03/2004
  • Est. Priority Date: 01/22/1998
  • Status: Expired due to Fees
First Claim
Patent Images

1. An isolated or purified mutated human fibroblast growth factor receptor-4 (FGFR-4), which comprises a point mutation in amino acid 388 of the wild-type human FGFR-4 having the amino acid sequence encoded by the nucleotide sequence of GenBank accession number X57205, wherein the point mutation results in replacement of glycine with arginine, and wherein the isolated and purified mutated human FGFR-4 is characterized by overexpression in a human cell as compared to the wild-type human FGFR-4 having the amino acid sequence encoded by the nucleotide sequence of GenBank accession number X57205 and/or tyrosine kinase activity in a human cell, which differs from the tyrosine kinase activity of the wild-type human FGFR-4 having the amino acid sequence encoded by the nucleotide sequence of GenBank accession number X57205.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×